Ginkgo Bioworks Collaborates With STRM.BIO And University Of British Columbia To Develop In Vivo Chimeric Antigen Receptor Therapies For Autoimmune Diseases
Benzinga Newsdesk 1 year ago
News
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseasesBOSTON, Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks
Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-
specific, and highly potent in vivo CAR therapies for autoimmune diseases
BOSTON, Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The partnership aims to develop in vivo chimeric antigen receptor (CAR) therapies for autoimmune diseases, leveraging Ginkgo's expertise in RNA construct design and immune cell engineering.